Index of Articles From 1994 TAGlines

About TAGlines

December, 1994
- Protease Scoreboard
  Planning for Efficacy Rates of 30-50%, Roche Protease Trials Shoot for Distant Stars
- The Imperiled NCDDG
  Twilight of NIH Drug Discovery Program Will Mean Even Slimmer Pickings for AIDS Therapeutic Pipeline
- Random Gleanings Vaccine Victory (Of Sorts), Inching Closer To An Animal Model for HIV, G.D. Searle's lead protease inhibitor crashed and burned...
November, 1994
- Interleukin-2: An Update
  Ten Years On, Feckless IL-2 Researchers Plod Ahead, Certain Of Success
- ACTG: Re-competition Blues
  Dazed and Confused, ACTG "Re"-Competitors Ready Themselves For The 1996-2001 Funding Cycle
- Yokohama: Malignancy Reportage
  Brouhaha Over Human Chorionic Gonadotropin (hCG) Yields, Again, To Sober Realism
October, 1994
- Star Gazing at the FDA
  Public Hearings At FDA Juxtapose Old Cries of Access With Those of Integrity, Accountability
- Yokohama Pathogenesis Update
  Improved Clinical Outcomes Wrought By Immunosuppressive Medicine and Second-Rate Immune Responses - Where Will It All End?
- The KS Project Report
  Research Paper Details Advances, Obstacles In The Treatment of Kaposi's Sarcoma
September, 1994
- Merck's Protease Plans
  Shot Down Early On, Merck Scientists Test Higher Doses And Combinations, Hoping for Success
- When (Not) To Start ARV Therapy
  Yokohama Roundtable Examines Treatment Quandary Facing Patients, Clinicians Alike
August, 1994
- Shiftless Cytokines
  Series of Research Papers Take To Task Would-Be Discoverers Of Cytokine Switch Scrutinizing the Knock-out Mice
- The Body in Question
  Garbage In, Garbage Out; Could It Be We're Asking Good Questions Of Bad Systems?
- Letter From Rockville
  Another meeting with the (FDA) Commissioner, Rockville, MD, 11 July 1994
July, 1994
- Not So Fast!
  With Its First Protease Trial Completed, Roche Races to FDA With Lukewarm Results, While Activists Cry 'Foul'
- Vaccine Dismay
  NIAID Scraps Large Scale Vaccine Trial -- And A Chastened Genentech Takes Its Case to The Hill
- ACTG Rescue Plan
  Tome of Recommendations Would Abolish ACDDC, Mandate Costing-Out and Establish Advisory Review Group
- A Word About TAG
  Information about TAG
June, 1994
- ACTG: Feet to the Fire
  Feet to the Fire, ACTG Investigators Scramble to Convince Industry They Can Produce
- The Intra-Company Cooperative
  ICC's Brainchild Designed to Show Every Drug and Every Combination a Success. Who Could Complain About That?
- d4T Approval Looms
  Accelerated Approval Guidelines Expedite Bristol's Launch of New Nucleoside -- In the Absence of Any Proof That It Works
May, 1994
- Targeting Kaposi's
  KS Proves Formidable Foe As Angiogenesis Inhibitors and Stealth Chemotherapy Fall Short of Expectations
- The Protease Quandary
  One Company's Search for an Effective Antiviral Contrasts Another's Scramble for the Easy Money
- Gene Therapy Redux
  Table
- Vexed Virologists
  Study After Study, Antiretroviral Analyses Confound More Than They Clarify

Back to the Treatment Action Group index page